<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="pharmaceutical-sciences" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Open Science Publishers LLP</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">229</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url">https://doi.org/10.31782/IJMPS.2023.13601</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmaceutical Sciences</subject></subj-group></article-categories><title-group><article-title>Novel Chalcones as Promising Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors&#13;
&#13;
__ampersandsignnbsp;&#13;
&#13;
__ampersandsignnbsp;&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kashyap</surname><given-names>Kamini</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>25</day><month>06</month><year>2023</year></pub-date><volume>)</volume><issue/><fpage>1</fpage><lpage>3</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>The current study focuses on the emerging idea of naturally occuring, chalcone-based inhibitors that will prevent angiogenic switching (fibroblast growth factor angiogenin, TGF-), which is prevented by directly inhibiting vascular endothelial growth factor receptor-2 (VEGFR-2), which prevents neovascularization, vascular formation, and network formation. The presented papers will encourage future researchers, pharmaceutical scientists, aspirant investigators, and related specialists to develop or look at potential angiogenic inhibitors.&#13;
</p></abstract><kwd-group><kwd>Angiogenesis</kwd><kwd> Cancer</kwd><kwd> Chalcone</kwd><kwd> Inhibition</kwd><kwd> Vascular endothelial growth factor</kwd><kwd> Vascular Endothelial Growth Factor Receptor-2</kwd></kwd-group></article-meta></front></article>
